On October 25, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, reported that Pierre Bélichard, CEO, will present an overview of the Company and participate in 1-on-1 meetings with institutional investors at the following investor meetings (Press release, Enterome, OCT 25, 2023, View Source [SID1234636326]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

10th China Healthcare Summit in Shanghai, China, November 2-3
– Enterome’s presentation is scheduled on November 2 at 2:45 pm in Function Room III.

Inv€$tival Showcase in London, UK, November 13
– Enterome’s presentation is scheduled at 10:30 am on Stage 3.

Jefferies’ London Healthcare Conference, UK, November 14-16
42ndP. Morgan Annual Healthcare Conference in San Francisco, USA,
January 8-11

Additionally, Enterome’s Senior Business Development Manager, Rachel Morra, will engage in 1-on-1 meetings with potential business partners at BIO-Europe, which will take place in Munich, Germany, on November 6-8.